BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15178811)

  • 1. Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
    Fernando NH; Hurwitz HI
    Oncologist; 2004; 9 Suppl 1():11-8. PubMed ID: 15178811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
    Herbst RS; Sandler AB
    Oncologist; 2004; 9 Suppl 1():19-26. PubMed ID: 15178812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on bevacizumab in metastatic colorectal cancer.
    McCormack PL; Keam SJ
    BioDrugs; 2008; 22(5):339-41. PubMed ID: 18778115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibitors in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in the treatment of breast cancer: rationale and current data.
    Rugo HS
    Oncologist; 2004; 9 Suppl 1():43-9. PubMed ID: 15178815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab: a review of its use in metastatic colorectal cancer.
    McCormack PL; Keam SJ
    Drugs; 2008; 68(4):487-506. PubMed ID: 18318567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the clinical development of bevacizumab.
    Chen HX
    Oncologist; 2004; 9 Suppl 1():27-35. PubMed ID: 15178813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in the treatment of colorectal cancer.
    Mulcahy MF; Benson AB
    Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.
    Lyseng-Williamson KA; Robinson DM
    BioDrugs; 2006; 20(3):193-5. PubMed ID: 16724868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).
    Zinser-Sierra JW; Rodríguez-Ramírez S; Villalobos-Valencia R; Ramírez-Márquez M
    Drugs R D; 2011; 11(2):101-11. PubMed ID: 21679003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in the treatment of metastatic colorectal cancer.
    Caprioni F; Fornarini G
    Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ; Grossbard ML; Kozuch PS
    Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-angiogenic treatment and colorectal cancer].
    André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab.
    Ellis LM
    Nat Rev Drug Discov; 2005 May; Suppl():S8-9. PubMed ID: 15962523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in the treatment of colorectal cancer.
    Cilley JC; Barfi K; Benson AB; Mulcahy MF
    Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing the potential of bevacizumab in cancer treatment.
    Bergsland E; Dickler MN
    Oncologist; 2004; 9 Suppl 1():36-42. PubMed ID: 15178814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.